Organization
Lexington, MA
5 abstracts
Abstract
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.Org: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
Use of gender-neutral language in clinical trial protocols in select cancers.Org: University of Kentucky, Lexington, KY, Lexington, MA, Kyowa Kirin Pharmaceutical Development,
Abstract
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.Org: Mary Crowley Cancer Research Center, Dallas, Next Oncology Virginia and Virginia Cancer Specialists, San Antonio Breast Cancer Symposium, Northwell Health Cancer Institute,
Abstract
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic College of Medicine, Takeda Development Center Americas, Inc., Lexington, MA, USA,
Abstract
Targeted inhibition of IRAK-4 with emavusertib on immune remodeling in metastatic brain melanoma.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, Gainesville, FL, University of Florida College of Public Health and Health Professions, Aileron Therapeutics, Watertown, MA,